Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis. J of Skin 2023, 7 (6), s251. https://doi.org/10.25251/skin.7.supp.251.